2023
Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US
Kc M, Fan J, Hyslop T, Hassan S, Cecchini M, Wang S, Silber A, Leapman M, Leeds I, Wheeler S, Spees L, Gross C, Lustberg M, Greenup R, Justice A, Oeffinger K, Dinan M. Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US. JAMA Network Open 2023, 6: e2323115. PMID: 37436746, PMCID: PMC10339147, DOI: 10.1001/jamanetworkopen.2023.23115.Peer-Reviewed Original ResearchConceptsLong-term survivorsCancer-specific mortalityColorectal cancerCancer cohortReceptor statusInitial diagnosisGleason scoreProstate cancerBreast cancerLong-term adult survivorsMedian cancer-specific survivalEnd Results cancer registryProstate-specific antigen levelRectal cancer cohortCancer-specific survivalStage III diseaseYear of diagnosisProgesterone receptor statusEstrogen receptor statusProportion of deathsSurvival time ratioEarly-stage cancerNononcologic outcomesIndex cancerLocalized diseaseFactors Associated With Receipt of Molecular Testing and its Impact on Time to Initial Systemic Therapy in Metastatic Non-Small Cell Lung Cancer
Osazuwa-Peters O, Wilson L, Check D, Roberts M, Srinivasan S, Clark A, Crawford J, Chrischilles E, Carnahan R, Campbell W, Cowell L, Greenlee R, Abbott A, Mosa A, Mandhadi V, Stoddard A, Dinan M. Factors Associated With Receipt of Molecular Testing and its Impact on Time to Initial Systemic Therapy in Metastatic Non-Small Cell Lung Cancer. Clinical Lung Cancer 2023, 24: 305-312. PMID: 37055337, DOI: 10.1016/j.cllc.2023.03.001.Peer-Reviewed Original ResearchConceptsInitial systemic treatmentSystemic treatmentMolecular testingComorbidity statusMetastatic non-small cell lung cancer patientsMetastatic non-small cell lung cancerTime-varying Cox regression modelsNon-small cell lung cancer patientsProportional hazardsNon-small cell lung cancerCell lung cancer patientsInitial systemic therapyMolecular testing ratesRetrospective cohort studyMajority of patientsCell lung cancerCox regression modelLung cancer patientsNon-Hispanic white individualsCox proportional hazardsYears of ageRace/ethnicityAdult patientsCohort studyPatient age
2022
Racial and Ethnic Variation in COVID-19 Vaccination Uptake Among Medicare Beneficiaries with Cancer History
Poghosyan H, Dinan MA, Tamamyan G, Nelson L, Jeon S. Racial and Ethnic Variation in COVID-19 Vaccination Uptake Among Medicare Beneficiaries with Cancer History. Journal Of Racial And Ethnic Health Disparities 2022, 10: 2354-2362. PMID: 36149576, PMCID: PMC9510246, DOI: 10.1007/s40615-022-01415-2.Peer-Reviewed Original ResearchConceptsNon-Hispanic white beneficiariesCancer historyVaccine doseMedicare beneficiariesWhite beneficiariesVaccine uptakeHispanic beneficiariesMultivariable logistic regression analysisCOVID-19 vaccination uptakeSelf-reported cancer historyCOVID-19 vaccine uptakeSelf-reported receiptCOVID-19 vaccination ratesLogistic regression analysisNon-Hispanic blacksSelf-reported raceUnvaccinated beneficiariesVaccination uptakeVaccine dosesVaccination ratesVaccine confidenceVaccine availabilitySupplement surveyCross-sectional dataEthnic variationMediators of Racial Disparity in the Use of Prostate Magnetic Resonance Imaging Among Patients With Prostate Cancer
Leapman MS, Dinan M, Pasha S, Long J, Washington SL, Ma X, Gross CP. Mediators of Racial Disparity in the Use of Prostate Magnetic Resonance Imaging Among Patients With Prostate Cancer. JAMA Oncology 2022, 8: 687-696. PMID: 35238879, PMCID: PMC8895315, DOI: 10.1001/jamaoncol.2021.8116.Peer-Reviewed Original ResearchConceptsProstate magnetic resonance imagingMagnetic resonance imagingPopulation-based cohort studyProstate cancerWhite patientsRacial disparitiesCohort studyMRI useIndividual-level socioeconomic statusEligible male patientsSocioeconomic statusNeighborhood-level socioeconomic statusLocalized prostate cancerProstate cancer diagnosisObserved racial disparitiesProstate magnetic resonanceMediation analysisPathologic factorsMale patientsUS SurveillanceBlack patientsMedicare databaseMAIN OUTCOMEUS adultsNew diagnosis
2021
Patterns and Predictors of Oral Anticancer Agent Use in Diverse Patients With Metastatic Renal Cell Carcinoma
Wheeler SB, Spees LP, Jackson BE, Baggett CD, Wilson LE, Greiner MA, Kaye DR, Zhang T, George D, Scales CD, Pritchard JE, Dinan MA. Patterns and Predictors of Oral Anticancer Agent Use in Diverse Patients With Metastatic Renal Cell Carcinoma. JCO Oncology Practice 2021, 17: e1895-e1904. PMID: 34138665, PMCID: PMC8678030, DOI: 10.1200/op.20.01082.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaOral anticancer agentsRenal cell carcinomaIndex dateCell carcinomaRisk ratioPatterns of usePatients age 80Patients age 18Population-based studyAdjusted risk differenceOral therapyPatient characteristicsContinuous enrollmentHigh frailtyAge 80Agent useRisk differencePatientsDiverse patientsComorbiditiesAge 18Regulatory approvalCarcinomaLog-Poisson modelPredictors of Chronic Opioid Use: A Population-Level Analysis of North Carolina Cancer Survivors Using Multi-Payer Claims
Check DK, Baggett C, Kim K, Roberts AW, Roberts MC, Robinson T, Oeffinger KC, Dinan MA. Predictors of Chronic Opioid Use: A Population-Level Analysis of North Carolina Cancer Survivors Using Multi-Payer Claims. Journal Of The National Cancer Institute 2021, 113: 1581-1589. PMID: 33881543, PMCID: PMC8562975, DOI: 10.1093/jnci/djab082.Peer-Reviewed Original ResearchConceptsChronic opioid useChronic opioid therapyOpioid useCancer survivorsOpioid therapyBaseline depressionLong-term pain managementSubstance useRetrospective cohort studyPopulation-based studyCancer registry dataLow-income survivorsCohort studyPatient characteristicsPain managementActive treatmentNonmetastatic cancerChronic useInsurance statusRelative riskRegistry dataOpioidsPoisson regressionYounger ageAge groupsReporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics
Varma T, Wallach JD, Miller JE, Schnabel D, Skydel JJ, Zhang AD, Dinan MA, Ross JS, Gross CP. Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics. JAMA Network Open 2021, 4: e217063. PMID: 33877309, PMCID: PMC8058642, DOI: 10.1001/jamanetworkopen.2021.7063.Peer-Reviewed Original ResearchConceptsNovel cancer therapeuticsPostmarketing studyBlack patientsCancer therapeuticsDemographic dataOlder adultsUS cancer populationUS Cancer StatisticsCross-sectional studyRace/ethnicityParticipants' demographic characteristicsPercentage of trialsPatient sexCancer populationClinical studiesCancer statisticsMAIN OUTCOMEDrug AdministrationFDA approvalStudy participantsCancer typesDemographic characteristicsDemographic informationStudy samplePatients
2017
Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset
Harowicz MR, Robinson TJ, Dinan MA, Saha A, Marks JR, Marcom PK, Mazurowski MA. Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset. Breast Cancer Research And Treatment 2017, 162: 1-10. PMID: 28064383, PMCID: PMC5909985, DOI: 10.1007/s10549-016-4093-4.Peer-Reviewed Original ResearchConceptsIntermediate-risk diseaseOncotype DX recurrence scoreHigh-risk diseaseDX recurrence scoreODX RSReceptor statusRecurrence scoreSurrogate markerProgesterone receptor statusInvasive breast cancerEstrogen receptor statusHigh-risk groupOngoing clinical trialsMagee EquationsPresence of patientsAdjuvant chemotherapyClinicopathologic dataRetrospective studyTumor sizeHER2 statusHistopathologic variablesClinical trialsBreast cancerPatient managementAdditional independent validation
2016
ONCOLOGISTS’ BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY
Roberts MC, Bryson A, Weinberger M, Dusetzina SB, Dinan MA, Reeder-Hayes K, Wheeler SB. ONCOLOGISTS’ BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY. International Journal Of Technology Assessment In Health Care 2016, 32: 355-361. PMID: 27958190, PMCID: PMC6526532, DOI: 10.1017/s026646231600060x.Peer-Reviewed Original ResearchConceptsAdjuvant chemotherapy decisionsBreast cancer patientsOncotype DXTreatment decisionsCancer patientsChemotherapy decisionsHormone receptor-positive breast cancer patientsClinical practiceReceptor-positive breast cancer patientsPositive breast cancer patientsOncotype DX useUnited States guidelinesProfiling testsEligible womenSurgical oncologistsCancer careClinical guidelinesModifiable barriersOncologistsMulti-level factorsPatientsThematic saturationPhone interviewsIntermediate scoresQualitative studyHow Many Lymph Nodes Are Enough? Assessing the Adequacy of Lymph Node Yield for Papillary Thyroid Cancer
Robinson TJ, Thomas S, Dinan MA, Roman S, Sosa JA, Hyslop T. How Many Lymph Nodes Are Enough? Assessing the Adequacy of Lymph Node Yield for Papillary Thyroid Cancer. Journal Of Clinical Oncology 2016, 34: 3434-3439. PMID: 27528716, PMCID: PMC6366339, DOI: 10.1200/jco.2016.67.6437.Peer-Reviewed Original ResearchConceptsPapillary thyroid cancerOccult nodal diseaseLymph nodesThyroid cancerNodal diseaseTumor stageNumber of LNsProphylactic central neck dissectionAdjuvant radioactive iodineLymph node examinationIntermediate-risk diseaseNational Cancer DatabaseMore lymph nodesNode-positive diseasePathologic tumor stagePrimary tumor stageCentral neck dissectionLymph node yieldLN yieldAdult patientsLN evaluationNeck dissectionNodal positivityNode examinationOccult disease
2015
Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer
Ruel E, Thomas S, Dinan MA, Perkins JM, Roman SA, Sosa JA. Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer. Endocrine 2015, 52: 579-586. PMID: 26708045, PMCID: PMC4880494, DOI: 10.1007/s12020-015-0826-0.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinomaCarcinoma, PapillaryCombined Modality TherapyDatabases, FactualFemaleHumansIodine RadioisotopesKnowledgeLymph NodesLymphatic MetastasisMaleMiddle AgedPostoperative PeriodPrognosisRadiotherapy DosageRisk FactorsSurvival AnalysisThyroid Cancer, PapillaryThyroid NeoplasmsThyroidectomyConceptsNegative lymph nodesPapillary thyroid cancerLow-risk papillary thyroid cancerLymph nodesCN0 patientsRAI useThyroid cancerPostoperative radioactive iodine administrationTrue nodal statusExcised lymph nodesLow-risk patientsLymph node statusRadioactive iodine administrationNegative surgical marginsOdds of receiptSurgical pathology specimensCut-point analysisPN0 patientsPN0 statusPostoperative RAIRAI administrationCervical lymphMultivariable adjustmentTotal thyroidectomyNodal statusRacial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer
Roberts MC, Weinberger M, Dusetzina SB, Dinan MA, Reeder-Hayes KE, Carey LA, Troester MA, Wheeler SB. Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer. Journal Of Clinical Oncology 2015, 34: 130-138. PMID: 26598755, PMCID: PMC4872005, DOI: 10.1200/jco.2015.63.2489.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBlack or African AmericanBreast NeoplasmsClinical Trials, Phase II as TopicConfounding Factors, EpidemiologicErbB ReceptorsFemaleGene Expression ProfilingHealthcare DisparitiesHumansInsurance CoverageLymphatic MetastasisMiddle AgedMolecular Targeted TherapyNeoplasm StagingNorth CarolinaPoisson DistributionPractice Guidelines as TopicPrecision MedicinePredictive Value of TestsResearch DesignRisk AssessmentRisk FactorsConceptsNode-positive breast cancerNon-black womenODX testingNode-negative patientsBreast cancerOncotype DXBlack patientsRacial disparitiesEarly-stage breast cancerCarolina Breast Cancer StudyGuideline-concordant careNode-positive patientsCancer care qualityPopulation-based studyOncotype DX testingQuality of careNorth Carolina womenLow socioeconomic statusMedium tumor sizeBlack womenBreast Cancer StudyAdjuvant chemotherapyMore comorbiditiesConcordant careTumor sizeOtolaryngology utilization of speech‐language pathology services for voice disorders
Cohen SM, Dinan MA, Kim J, Roy N. Otolaryngology utilization of speech‐language pathology services for voice disorders. The Laryngoscope 2015, 126: 906-912. PMID: 26308555, DOI: 10.1002/lary.25574.Peer-Reviewed Original ResearchConceptsLaryngeal/voice disordersSpeech-language pathology servicesSLP evaluationLaryngeal diagnosisDiagnosis changeSLP servicesVoice disordersMultivariable logistic regression analysisPathology servicesClinical Modification codesLogistic regression analysisVoice therapy sessionsPatient ageHealthcare utilizationInitial diagnosisPatient factorsNinth RevisionUnique patientsStudy criteriaVoice-disordered patientsRetrospective analysisStudy populationInternational ClassificationGreater oddsPatientsMinimally Invasive Versus Open Pancreaticoduodenectomy for Cancer
Adam MA, Choudhury K, Dinan MA, Reed SD, Scheri RP, Blazer DG, Roman SA, Sosa JA. Minimally Invasive Versus Open Pancreaticoduodenectomy for Cancer. Annals Of Surgery 2015, 262: 372-377. PMID: 26158612, DOI: 10.1097/sla.0000000000001055.Peer-Reviewed Original ResearchConceptsShort-term outcomesOpen pancreaticoduodenectomyMajority of hospitalsOpen surgeryInvasive Versus Open PancreaticoduodenectomyNational practice patternsSingle institutional experiencePositive surgical marginsLength of stayNeuroendocrine tumor diagnosisMultivariable adjustmentAdult patientsLymph nodesSurgical marginsInvasive pancreaticoduodenectomyOpen procedurePractice patternsInstitutional experiencePancreaticoduodenectomyMultivariable modelingMortality ratePatientsPatient safetyMIPDTumor diagnosisPresence and Number of Lymph Node Metastases Are Associated With Compromised Survival for Patients Younger Than Age 45 Years With Papillary Thyroid Cancer
Adam MA, Pura J, Goffredo P, Dinan MA, Reed SD, Scheri RP, Hyslop T, Roman SA, Sosa JA. Presence and Number of Lymph Node Metastases Are Associated With Compromised Survival for Patients Younger Than Age 45 Years With Papillary Thyroid Cancer. Journal Of Clinical Oncology 2015, 33: 2370-2375. PMID: 26077238, DOI: 10.1200/jco.2014.59.8391.Peer-Reviewed Original ResearchConceptsCervical lymph node metastasisAge 45 yearsLymph node metastasisPapillary thyroid cancerMetastatic lymph nodesAmerican Joint CommitteeOverall survivalNode metastasisMetastatic nodesLymph nodesNodal metastasisThyroid cancerJoint CommitteeAssociation of OSPatients age 45 yearsNational Cancer Data BaseCurrent American Joint CommitteeMore positive nodesLow-risk diseasePresence of lymphAdditional mortality riskPositive nodesPreoperative screeningAdult patientsSEER databaseAdjuvant Radioactive Iodine Therapy Is Associated With Improved Survival for Patients With Intermediate-Risk Papillary Thyroid Cancer
Ruel E, Thomas S, Dinan M, Perkins JM, Roman SA, Sosa JA. Adjuvant Radioactive Iodine Therapy Is Associated With Improved Survival for Patients With Intermediate-Risk Papillary Thyroid Cancer. The Journal Of Clinical Endocrinology & Metabolism 2015, 100: 1529-1536. PMID: 25642591, PMCID: PMC4399282, DOI: 10.1210/jc.2014-4332.Peer-Reviewed Original ResearchConceptsRadioactive iodine therapyPapillary thyroid cancerIntermediate-risk papillary thyroid cancerAdjuvant radioactive iodine therapyIntermediate-risk PTC patientsImproved overall survivalIntermediate-risk patientsOverall survivalRisk of deathRAI therapyIodine therapyPTC patientsThyroid cancerAmerican Thyroid Association riskLong-term prognosisAmerican Joint CommissionCommon endocrine malignancyPaucity of dataTotal thyroidectomyAdult patientsMultivariate adjustmentClinical factorsAggressive variantStage T3Patient groupImpact of Extent of Surgery on Survival for Papillary Thyroid Cancer Patients Younger Than 45 Years
Adam M, Pura J, Goffredo P, Dinan MA, Hyslop T, Reed SD, Scheri RP, Roman SA, Sosa JA. Impact of Extent of Surgery on Survival for Papillary Thyroid Cancer Patients Younger Than 45 Years. The Journal Of Clinical Endocrinology & Metabolism 2015, 100: 115-121. PMID: 25337927, PMCID: PMC5399499, DOI: 10.1210/jc.2014-3039.Peer-Reviewed Original ResearchConceptsPapillary thyroid cancer patientsTotal thyroidectomyOverall survivalThyroid cancer patientsImpact of extentYears of ageCancer patientsNational Cancer Data BaseUnadjusted overall survivalLymph node diseaseExtent of resectionEnd Results (SEER) datasetAdult patientsClinical characteristicsExcellent prognosisNode diseasePathologic factorsImproved survivalThyroid lobectomyTumor sizeCurrent guidelinesMultivariable modelingLobectomyMAIN OUTCOMEThyroidectomy
2014
Costs, Effectiveness, and Workload Impact of Management Strategies for Women With an Adnexal Mass
Havrilesky LJ, Dinan M, Sfakianos GP, Curtis LH, Barnett JC, Van Gorp T, Myers ER. Costs, Effectiveness, and Workload Impact of Management Strategies for Women With an Adnexal Mass. Journal Of The National Cancer Institute 2014, 107: dju322. PMID: 25515232, DOI: 10.1093/jnci/dju322.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAlgorithmsBiomarkers, TumorCA-125 AntigenCost-Benefit AnalysisDecision MakingDisease ManagementFemaleGenital Neoplasms, FemaleHumansMaleMarkov ChainsMedicareMembrane ProteinsMiddle AgedPostmenopausePractice Guidelines as TopicPremenopauseReferral and ConsultationRisk AssessmentSEER ProgramSensitivity and SpecificityUnited StatesWorkloadConceptsPostmenopausal womenAdnexal massesCutoff valueEnd Results-MedicareState Inpatient DatabasesGynecologists guidelinesBiomarker validation studiesPremenopausal womenClinical outcomesGynecologic oncologistsInpatient DatabaseMalignancy AlgorithmSurgical volumeReferral strategiesTriage strategiesMedical costsRelative survivalPhysician workloadCA125Test characteristicsCost-effective strategyWomenTest sensitivityAmerican CongressMedicare reimbursementExtent of Surgery for Papillary Thyroid Cancer Is Not Associated With Survival
Adam MA, Pura J, Gu L, Dinan MA, Tyler DS, Reed SD, Scheri R, Roman SA, Sosa JA. Extent of Surgery for Papillary Thyroid Cancer Is Not Associated With Survival. Annals Of Surgery 2014, 260: 601-607. PMID: 25203876, PMCID: PMC4532384, DOI: 10.1097/sla.0000000000000925.Peer-Reviewed Original ResearchConceptsPapillary thyroid cancerExtent of surgeryTotal thyroidectomyOverall survivalTumor sizeDistant metastasisThyroid cancerSurvival advantagePTC tumorsRadioactive iodine treatmentLarge contemporary cohortOverall survival advantageUnderwent total thyroidectomyProportional hazards modelPresence of nodalMultivariable adjustmentAdult patientsClinical factorsContemporary cohortMultifocal diseaseAbsolute indicationMale sexTumors 1.0Black racePTC patientsTreatment Patterns and Outcomes for Patients with Adrenocortical Carcinoma Associated with Hospital Case Volume in the United States
Gratian L, Pura J, Dinan M, Reed S, Scheri R, Roman S, Sosa JA. Treatment Patterns and Outcomes for Patients with Adrenocortical Carcinoma Associated with Hospital Case Volume in the United States. Annals Of Surgical Oncology 2014, 21: 3509-3514. PMID: 25069860, PMCID: PMC4515350, DOI: 10.1245/s10434-014-3931-z.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex NeoplasmsAdrenocortical CarcinomaAdultAgedDatabases, FactualElective Surgical ProceduresFemaleFollow-Up StudiesHospitals, High-VolumeHospitals, Low-VolumeHumansLength of StayMaleMiddle AgedNeoplasm StagingOutcome and Process Assessment, Health CarePractice Patterns, Physicians'RegistriesReoperationSurvival RateWorkloadConceptsHigh-volume centersLow-volume centersHospital case volumeOverall survivalTreatment patternsCase volumeRegional lymph node evaluationAggressive surgical resectionLymph node evaluationPrimary adrenal malignancyMedian overall survivalNational Cancer DatabasePostoperative mortality rateBackgroundAdrenocortical carcinomaChemotherapy useAggressive treatmentRadical resectionReadmission ratesSurgical resectionAdrenal malignancyCarcinoma AssociatedClinical outcomesTumor characteristicsACC patientsAggressive disease